Expanded Research Pipeline

Beyond bioidentical hormone therapy, BioBel’s R&D portfolio strategically expands into metabolic optimisation, neuroendocrine ageing, reproductive longevity, and precision diagnostics.

Each programme addresses critical unmet needs in the global endocrine therapeutics landscape, with clear pathways to clinical validation and commercialisation.

E

Status
Phase 2 Ready

BioBel-E

Dual Capsule Bioidentical Hormone Therapy

Flagship programme targeting menopausal and andropausal health through circadian-aligned hormone delivery. Addresses vasomotor symptoms, bone health, cardiovascular protection, and quality of life in both women and men experiencing age-related hormonal decline.

M

Status
Pre-Clinical

BioBel-M

Hormonal-Metabolic Optimisation

Novel therapeutic approach targeting insulin resistance and weight regulation through strategic hormone modulation. Combines metabolic hormones with supportive nutrients to restore insulin sensitivity, optimise body composition, and reduce cardiovascular risk factors.

N

Status
Pre-Clinical

BioBel-N

Neuroendocrine Support Formulations

DHEA and pregnenolone formulations supporting cognition, mood stability, and sleep architecture. Targets age-related decline in neurosteroid production, with potential applications in cognitive decline prevention and mood disorder management.

R

Status
Discovery

BioBel-R

Reproductive Longevity Platform

Innovative peptide-hormone hybrid therapeutics for ovarian and testicular longevity. Aims to extend reproductive healthspan, preserve fertility potential, and maintain sexual health through targeted gonadal support.

D

Status
Development

BioBel-D

AI-Powered Hormone Diagnostics

Machine learning platform for individualised therapy optimisation. Integrates multi-timepoint hormone measurements, genetic markers, and clinical response data to predict optimal treatment protocols for each patient.

Manufacturing &
Regulatory Platform

BioBel ensures international compliance with IND-aligned (FDA) and CTN (TGA) frameworks, positioning our programmes for multi jurisdictional approval.

Our regulatory strategy is built on proactive engagement with global health authorities, ensuring that our development pathway meets the highest standards of evidence generation.

All investigational products are manufactured in GMP-certified facilities, with validated potency, uniformity, and stability testing conducted under ICH guidelines.

Every batch undergoes comprehensive analytical testing including:

  • High-performance liquid chromatography (HPLC) for active ingredient quantification
  • Dissolution testing to ensure bioavailability
  • Microbial limits testing and sterility assurance
  • Stability studies under accelerated and long-term conditions
  • Container closure integrity testing

Safety First

Comprehensive pharmacovigilance systems track adverse events in real-time, with immediate reporting protocols to regulatory authorities.

Scalability

Manufacturing processes designed for seamless transition from clinical supply to commercial-scale production without reformulation.

Compliance

Quality management systems aligned with ISO 13485, ICH Q7-Q11, and regional GMP standards across all target markets.

Our regulatory infrastructure includes dedicated quality assurance personnel, validated computerised systems for batch record management, and established relationships with regulatory consultants in Australia, United States, European Union, and Asia-Pacific regions.

This robust platform ensures that BioBel can navigate complex global regulatory landscapes efficiently whilst maintaining unwavering commitment to patient safety.